belimumab
Sign in to saveAlso known as LymphoStat-B, Lymphostat-B Benlysta
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.
Key facts
- Drug.O
- 2010
- Drug.S
- 44
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458612180
- Drug.type
- mab
- Drug.image
- Belimumab 5Y9K.png
- Drug.caption
- Fab fragment of belimumab. .
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- B-cell activating factor (BAFF, BLyS)
- Drug.tradename
- Benlysta
- Drug.MedlinePlus
- a611027
- Drug.DailyMedID
- Belimumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous, subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG04
via Wikipedia infobox
Research
1,491 papers- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.The New England journal of medicine · 2020
- Belimumab for systemic lupus erythematosus.The Cochrane database of systematic reviews · 2021
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2011
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis and rheumatism · 2011
- Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.Clinical journal of the American Society of Nephrology : CJASN · 2022
via PubMed
Wikidata facts
- Instance of
- antibody
- Subclass of
- chemical compound
- Mass
- 126450.30
- Image
- Belimumab 5Y9K.png
- Has use
- medication
Show 10 more facts
- World Health Organisation international non-proprietary name
- belimumab
- defined daily dose
- 25
- subject has role
- monoclonal antibody
- medical condition treated
- lupus nephritis
- chemical formula
- C₆₇₁₄H₁₀₄₂₈O₂₁₀₂S₅₂
- Commons category
- Belimumab
- has characteristic
- biopharmaceutical
- physically interacts with
- TNF superfamily member 13b
- trading name
- Benlysta
- route of administration
- intravenous injection
Sources (7)
via Wikidata · CC0
~10 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects and interactions
- Mechanism of action
- History
- Society and culture
- Legal status
- Economics
- Research
- References
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.
The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).
Excerpted from Wikipedia’s “belimumab” article, available under the CC BY-SA 4.0 licence.